CTOR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Citius Oncology Inc (CTOR) is not a strong buy for a beginner, long-term investor at this time. The stock shows no significant positive catalysts, weak financial performance, and bearish technical indicators. With no recent trading signals or positive sentiment, it is better to wait for more favorable conditions before investing.
The technical indicators are bearish. The MACD histogram is negative and expanding downward, RSI is neutral at 31.877, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels, with the next support at 1.054.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
Bearish technical indicators, declining financial performance (negative EPS growth and net income), and lack of positive sentiment or trading signals.
In Q1 2026, revenue remained flat at $3,944,111 (0.00% YoY), net income dropped by -16.90% YoY to -$5,534,069, and EPS declined by -33.33% YoY to -0.06. Gross margin remained stable at 79.99%. Overall, the financial performance is weak with no growth trends.
No data available for analyst ratings or price target changes.
